Ventricular fibrillation threshold (VFRT) in experimental coronary occlusion: comparative studies on the effect of G-I-K solution and some new antiarrhythmic agents.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004285:Dogs; D004562:Electrocardiography; D005947:Glucose / Q000627:therapeutic use*; D006400:Hematocrit; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D007328:Insulin / Q000627:therapeutic use*; D007773:Lactates / Q000378:metabolism; D008012:Lidocaine / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications* / Q000378:metabolism; D009206:Myocardium / Q000032:analysis; D010672:Phenytoin / Q000627:therapeutic use*; D011188:Potassium / Q000032:analysis / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D011773:Pyruvates / Q000378:metabolism; D012964:Sodium / Q000032:analysis; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D007328:Insulin; D007773:Lactates; D011773:Pyruvates; D010672:Phenytoin; D008012:Lidocaine; D012964:Sodium; D005947:Glucose; D011188:Potassium